The Pharma Data

MARCH 13, 2021

Further, prespecified exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in patients affected by Alzheimer’s disease. Lilly’s chief scientific officer and president of Lilly Research Laboratories. Apostolova, M.D.,

Disease 40

Disease Trials Treatment Medical Schools 40

The Pharma Data

AUGUST 15, 2021

WELIREG Approved for Adult Patients With VHL Disease Who Require Therapy for Associated Renal Cell Carcinoma, Central Nervous System Hemangioblastomas, or Pancreatic Neuroendocrine Tumors, Not Requiring Immediate Surgery. The recommended dose of WELIREG (40 mg tablets) is 120 mg once daily until disease progression or unacceptance toxicity.

Treatment 52

Treatment Disease Clinical Trials Therapies 52

The Pharma Data

MARCH 8, 2021

“We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases,” shared Dr. Wendy Painter, Chief Medical Officer of Ridgeback Biotherapeutics. “At About Molnupiravir. About Ridgeback Biotherapeutics.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

JULY 12, 2021

The data were presented during the late-breaking clinical trials session at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

Elrig

APRIL 29, 2025

Understanding the role of neuroimmune interactions has become increasingly important in tackling complex neurological diseases. Matthew Fell, Forum Director and Executive Director of Neuroimmunology,MSD ,is responsible for leading a team of scientists focused on the discovery of neuroimmune based therapies for neurodegenerative diseases.

Drugs 52

Drugs Science Clinical Trials Laboratories 52

The Pharma Data

NOVEMBER 19, 2020

Gelbman most recently served as the founding CEO of FDNA, a digital health startup that develops advanced AI tools to help diagnose patients with rare diseases. Patel currently serves as the director of Infectious Diseases Research Laboratory at the Mayo Clinic, as well as co-director of the clinical Bacteriology Laboratory.

Laboratories 52

Laboratories Research Laboratories Science Organic Chemistry 52

The Pharma Data

OCTOBER 12, 2021

The winning research receives 5,000 USD and a bronze horse for the research that has the highest translational potential; the investigator is awarded with 1,000 USD and the research laboratory 4,000 USD to continue the great work. We develop solutions and provide services to protect animals from disease and pain.

Research Laboratories 52

Research Laboratories Laboratories Therapies Production 52

The Pharma Data

AUGUST 31, 2021

“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

FDA Approval 52

FDA Approval Treatment FDA Research Laboratories 52

The Pharma Data

AUGUST 7, 2020

The ARM report also showcased robust pipelines of therapies targeting indications in cancers, infectious diseases and inherited disorders. These manufactured antibodies have been developed and manufactured by Eli Lilly and Company ’s Lilly Research Laboratories in a partnership with AbCellera. Dr. Francis S.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

NIH Director's Blog: Drug Development

MARCH 11, 2014

Credit: Jane Ades, National Human Genome Research Institute, NIH Type 2 diabetes (T2D) tends to run in families, and over the last five years the application of genomic technologies has led to discovery of more than 60 specific DNA variants that contribute to risk. 2012;7(7):e40972. Link: Accelerating Medicines Partnership.

DNA 52

DNA Drugs Disease Research Laboratories 52

The Pharma Data

JUNE 1, 2022

Under her leadership, Pfizer advanced into clinical development or approval bacterial vaccine programs directed at the prevention of diseases due to Streptococcus pneumoniae, Group B Streptococcus, Neisseria meningitidis, Staphylococcus aureus, and Clostridium difficile. Dr. Anderson joined Pfizer via Wyeth in 2007.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

MARCH 16, 2021

This collaboration with the Lieber Institute further expands our innovative neuropsychiatric research program, a key focus area at Boehringer Ingelheim, with a first-in-class mechanism that may have the potential to address these symptoms,” said Dr. Hugh Marston, Ph.D., Head of Department CNS Diseases Research at Boehringer Ingelheim. “By

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

OCTOBER 19, 2020

Pneumococcal disease in adults is on the rise globally, in part driven by disease-causing serotypes not targeted by the currently available pneumococcal conjugate vaccine,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

Codon

DECEMBER 10, 2023

If you have protein libraries in your research laboratory, please send them to us (datasets@alignbio.org) for analysis. The biggest challenge will be to acquire DNA that encodes millions of different proteins. Synthesizing that much DNA is cost-prohibitive. We’ll analyze the proteins and provide you with expression data for free.

Protein Expression 114

Protein Expression Laboratories DNA Engineering 114

The Pharma Data

JUNE 2, 2023

Many patients with mCRPC are only able to receive one line of therapy, as the disease can progress quickly. In the U.S., prostate cancer is the second most common cancer in men, and despite an increase in the number of available therapies for patients with mCRPC, five-year survival remains low.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

MARCH 30, 2021

“KEYTRUDA has become an important treatment option for certain patients with locally advanced or metastatic bladder cancer in the European Union and other countries around the world,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We Head and Neck Squamous Cell Cancer. Cervical Cancer.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

SEPTEMBER 17, 2020

Lilly ‘s chief scientific officer and president of Lilly Research Laboratories. This is yet another example of the ways our industry is closely collaborating to combat this devastating disease and help patients around the world access new therapies.”

Therapies 52

Therapies Production Government Disease 52

The Pharma Data

MARCH 5, 2021

In the Phase 2, patients are enrolled across various cohorts, depending on disease type and prior therapy. Loxo Oncology at Lilly was created in December 2019, combining the Lilly Research Laboratories oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019. The primary endpoint for Phase 2 is ORR.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials Therapies 52

Codon

DECEMBER 10, 2023

If you have protein libraries in your research laboratory, please send them to us (datasets@alignbio.org) for analysis. The biggest challenge will be to acquire DNA that encodes millions of different proteins. Synthesizing that much DNA is cost-prohibitive. We’ll analyze the proteins and provide you with expression data for free.

Protein Expression 91

Protein Expression Laboratories DNA Engineering 91

The Pharma Data

JULY 12, 2021

“Our decades-long commitment to fighting the epidemic is stronger than ever as we continue to build on our legacy of research and innovation in HIV,” said Dr. Joan Butterton, vice president, Global Clinical Development, Infectious Diseases, Merck Research Laboratories. “We

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

PPD

OCTOBER 12, 2023

Since chimeric antigen receptor T cell (CAR-T) therapy was first approved in 2017, there has been a marked increase of cell and gene therapy studies resulting in significant changes in the way diseases are treated as well as patient outcomes.

Laboratories 52

Laboratories Clinical Trials Protein Expression Pharmacokinetics 52

The Pharma Data

APRIL 11, 2021

50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity. Retevmo has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction. 15 to 89 mL/min, estimated by Modification of Diet in Renal Disease [MDRD] equation). Retevmo is an U.S.

Research 52

Research Treatment Therapies Trials 52

FDA Law Blog: Biosimilars

DECEMBER 11, 2023

24] These submissions all related to a single disease. FDA’s own estimates would result in an influx of premarket submissions, in a six-month period, that would be 40 times greater than the number of COVID submissions and related to an extraordinarily diverse set of diseases and conditions. 68006, 68012 (Oct.

FDA 69

FDA Laboratories Regulations Production 69

The Pharma Data

DECEMBER 17, 2020

Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. He spent 27 years at Merck & Co. Immune Regulation – U.K.-based based Immune Regulation Ltd.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

Drug Target Review

AUGUST 28, 2024

What are the main challenges currently faced in the treatment of chronic liver diseases, and how does Resolution Therapeutics aim to address these challenges? Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years.

Therapies 116

Therapies Disease Engineering Medical Schools 116

Alta Sciences

APRIL 4, 2025

Getting to the Heart of Science: How Clinical Research Saved My Life and Continues to Inspire Me pmjackson Fri, 04/04/2025 - 18:01 By Josiah Liang, Research Laboratory Technician, Clinical Diagnostic and Central Laboratory Services. How Clinical Research Saved My Life I was born in 2000.

Clinical Research 52

Clinical Research Science Research Research Laboratories 52

The Pharma Data

APRIL 8, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. In the U.S. About KEYTRUDA ® (pembrolizumab) Injection, 100 mg.

Therapies 52

Therapies Disease Treatment Research Laboratories 52

The Pharma Data

SEPTEMBER 21, 2020

First-line treatments for patients with ovarian cancer are designed to delay the disease’s progression for as long as possible to help achieve long-term remission. The PAOLA-1 trial showed that the combination of Lynparza with bevacizumab as a maintenance treatment reduced the risk of disease progression or death by 67%.

Research Laboratories 52

Research Laboratories Treatment Trials Laboratories 52

The Pharma Data

MARCH 16, 2021

inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational candidate in Merck’s oncology pipeline, for the potential treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), not requiring immediate surgery. in patients with VHL disease-associated RCC.

FDA 52

FDA Disease Trials Drugs 52

The Pharma Data

JULY 8, 2021

This approval is based on data from the second interim analysis of the Phase 2 KEYNOTE-629 trial, in which KEYTRUDA demonstrated an objective response rate (ORR) of 50% (95% CI, 36-64) (n=54), including a complete response rate of 17% and a partial response rate of 33% in the cohort of patients with locally advanced disease.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

JULY 6, 2021

Food and Drug Administration (FDA)-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, human epidermal growth factor receptor 2 (HER2)/neu-targeted therapy. 1)] as determined by a U.S. Head and Neck Squamous Cell Cancer.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

JULY 21, 2021

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Forward-Looking Statement of Merck & Co., Kenilworth, N.J.,

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

The Pharma Data

NOVEMBER 22, 2020

PAH is a chronic, progressive disease caused by the hardening and narrowing of the pulmonary arteries that can cause right heart failure and eventual death. The drug also received Rare Pediatric Disease Designation for these indications. It was granted Priority Review. with LEPR deficiency obesity. Featured Jobs on BioSpace.

FDA 52

FDA Licensing Licensing Treatment 52

The Pharma Data

AUGUST 30, 2021

“We are pleased to offer two potential new treatment options with KEYTRUDA for patients in Japan based on compelling data from our clinical trial program,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5),

Treatment 52

Treatment Trials Research Laboratories Clinical Trials 52

The Pharma Data

NOVEMBER 18, 2021

For over 130 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Source link: [link].

Clinical Trials 52

Clinical Trials Treatment Trials RNA 52

The Pharma Data

JANUARY 24, 2021

Li, president, Merck Research Laboratories. “We For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Kenilworth, N.J.,

Vaccine 40

Vaccine Immune Response Virus Production 40